{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"246"},{"groupId":"OG001","spread":"114","value":"469"},{"groupId":"OG002","spread":"173","value":"582"},{"groupId":"OG003","spread":"228","value":"731"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"6"}],"units":"Participants"}],"description":"Mean with standard deviation of average serum concentration curve at steady state by dose level.","dispersionType":"Standard Deviation","groups":[{"description":"PF-02341066 165 mg/m²/dose BID","id":"OG000","title":"Dose Level 3"},{"description":"PF-02341066 215 mg/m²/dose BID","id":"OG001","title":"Dose Level 4"},{"description":"PF-02341066 280 mg/m²/dose BID","id":"OG002","title":"Dose Level 5"},{"description":"PF-02341066 365 mg/m²/dose BID","id":"OG003","title":"Dose Level 6"}],"paramType":"MEAN","populationDescription":"Steady state PK sampling was not performed during enrollment on dose level 1 or 2. In Phase 2, PK was optional and for those who consented data is included with dose level 5. Steady state PK samples were obtained on a day between day 15 and 28 of cycle 1, pre-dose, 1, 2, 4, 6-8 h post-dose","reportingStatus":"POSTED","timeFrame":"Cycle 1 (day 15-28) pre-dose, 1, 2, 4, 6-8 hours post-dose","title":"Steady State C Average of Crizotinib","type":"PRIMARY","unitOfMeasure":"ng/mL"}